CBB ..there is a view that Amgen with their Repatha salesforce in the US and NVS in the EU with their salesforce ..could bring Vascepa to a wider market far faster then AMRN Just stating that as a current view Kiwi
I've been using a $50 BO price as part of my retirement financial planning for years, but will happily accept Ajax's $73/shr target! I think most long time longs are going to be sitting tight, only traders are selling their shares so they can move on to their next big play - the folks who aim to hit a bunch of singles and doubles instead of a the Earl Weaver preferred 3-run homerun.
Market Data 
Markets 
AI
